echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > ASCO breast cancer guideline update: HER2 low expression breast cancer ushered in a new program!

    ASCO breast cancer guideline update: HER2 low expression breast cancer ushered in a new program!

    • Last Update: 2022-09-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    *For medical professional reading reference only

    Come and learn!


    Screenshots of guidelines published


    Scan the QR code above to get more information on cancer guidelines


    DS8201

    Can be used for HER2 low expression/positive metastatic breast cancer


    The guideline update recommends that DS8201 should be used in patients with HER2 IHC 1+/IHC 2+ and ISH-negative metastatic breast cancer who have received at least first-line chemotherapy for metastatic disease, and those who are hormone receptor-positive and refractory to endocrine therapy (based on Evidence-based evidence, benefits outweigh harms; quality of evidence: moderate; strength of recommendation: strong recommendation)



    The recommended evidence for DS8201 in the guideline is based on DESTINY- Breast04 , a phase III, two-group, open-label, randomized, multicenter clinical trial:


    Figure 1A


    Figure 1C


    Figure 1B


    Figure 1D


    Figure 2-1


    Figure 2-2


    Figure 2-3



    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.